ClinicalTrials.gg
CompletedNCT00701285SAPHIREUpdated May 14, 2014

South Korean Pitavastatin Heart Failure Study

A Phase 4 interventional study of pitavastatin and pravastatin in Chronic Heart Failure, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-05-14.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 148 studies in Heart Failure with a site in Korea, Republic of — 49 open to participants now, 54 under way, 12 of them phase 3. Heart Failure · Korea, Republic of.

Planned enrollment
88th of 109
70 · median 227
Started
2008
with 1 other
Phase 4
15 of 148
4 open now
Registered
5th of 148
by date

Among the 148 studies in Heart Failure with a site in Korea, Republic of, this one is the 88th largest by planned enrollment of the 109 interventional ones that give a count, is one of 2 that started in 2008, is one of 15 in phase 4, and was the 5th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

49 of the 148 studies in Heart Failure with a site in Korea, Republic of are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Heart Failure with a site in Korea, Republic of, or all of them as a file.
02

Study summary

We want to evaluate the utility of statins on heart function according to potency. Patients with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for 52 weeks. Then we evaluate the effect of pitavastatin and pravastatin primarily on rate of hospitalization for cardiovascular cause and lipid profile secondarily biomarker, echocardiography parameter, 6-minute walk, change of NYHA class distribution, cardiovascular mortality.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • heart failure
  • pitavastatin
  • pravastatin
  • statin
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who accepted to enter the study by written
  2. Age ≥ 30 years
  3. LDL-cholesterol ≥ 70mg/dl
  4. Chronic heart failure of :

    • class II \~ III
    • Ischemic etiology
    • \< 45%
    • Optimal therapy for chronic heart failure and stable clinical condition over the two weeks.

Exclusion criteria

Exclusion Criteria:

  1. Patients who participated in other studies 3 months before enrollment
  2. Statin treatment within 2 months before enrollment
  3. Unstable decompensated heart failure at enrollment
  4. Acute coronary syndrome or cerebral vascular disease within 3 months before enrollment
  5. Coronary revascularization within 3 months before enrollment or planned at enrollment
  6. Any other serious disease or condition which might effect such as , life-threatening infectious disease.
  7. Serum creatinine levels >= 3.0 mg/dl
  8. or AST levels >=2.5 times of
  9. CK levels >=2 times of ULN
  10. Uncontrolled hypothyroidism : TSH level >= 2 times of ULN
  11. Pregnant or breastfeeding women, women who want to bearing
  12. Patients who might to be unsuitable by the decision of investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    1

    strong statin

    Drug: pitavastatin

  • Active comparator
    2

    mild statin

    Drug: pravastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Rate and number of hospitalization for cardiovascular cause; Lipid profile

    Time frame: 52week

Secondary outcomes

  1. Biomarker : BNP, hsCRP, IL-6. TNF-α

    Time frame: 52 week

  2. Echocardiography : LVEF, E/A ratio, LVEDD, LVESD

    Time frame: 52 week

  3. Cardiac function evaluation (NYHA class distribution, 6-minute walk test)

    Time frame: 52 week

  4. Cardiovascular mortality

    Time frame: 52 week

07

Study locations

1 site
  • SEOUL St. Mary's Hospital
    Seoul, Seocho-Ku 137-040, Korea, Republic of
08

References and documents

Publications

  • Lee HY, Cho HJ, Kim HY, Jeon HK, Shin JH, Kang SM, Baek SH. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med. 2014 Nov;29(6):754-63. doi: 10.3904/kjim.2014.29.6.754. Epub 2014 Oct 31. PubMed 25378974 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2008
First posted
Jun 19, 2008
Start
Jul 2008
Primary completionActual
May 2013
CompletionActual
May 2014
Last update
May 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00701285
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jun 19, 2008
Start date
Jul 2008
Primary completion
May 2013
Completion
May 2014
Last update
May 14, 2014

Study contacts

Sang Hong Baek, MD, PhD
study chair · KangNam St. Mary's Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pitavastatin · Pravastatin

Start the discussion